Heron Therapeutics has experienced a setback following a court ruling that invalidated its patent for the Cinvanti drug, which is used to prevent nausea and vomiting associated with chemotherapy. The decision comes after a legal challenge that questioned the validity of the patent claims held by Heron. As a result of this ruling, the company may face increased competition in the market for antiemetic medications. The implications of this case could affect Heron's market position and future revenue from Cinvanti.
Related Articles
Don't miss out on breaking stories and in-depth articles.